Diversified health care company combining a diagnostics lab (BioReference), a pharmaceutical pipeline and specialty products.
Diversified health care company combining a diagnostics lab (BioReference), a pharmaceutical pipeline and specialty products.
Collects royalties and milestone payments from partners that sell its drugs, notably Pfizer for the growth hormone Ngenla (somatrogon), while selling Rayaldee itself. Phillip Frost, the chairman, is the largest shareholder.
Moat: none (scale). Diversified but sub-scale mix of lab testing and pharma assets lacks a clear single competitive advantage.
Headquarters: Miami, Florida · Employees: 2,275
Size OPKO Health (OPK) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.25B, the 2089th largest of 3,085 United States companies the cockpit tracks. Shares closed at $1.69 on 18 Nov 2026.
Performance Over six months the shares gained 37.4%, against +14.4% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue fell 21.9% over the last twelve months (peer median +9.2%); the operating margin is -29.1% (peer median 5.0%).
Valuation It trades at 2.8× enterprise value to sales against a peer median of 1.8× (6th most expensive of 21).
Capital Return on invested capital runs 19.9 points below its cost of capital (10.6% WACC).
Credit OPKO Health has 1 bond outstanding ($121M).
Short interest Short interest is 4.4% of the free float (30 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $502M | $607M | $713M | $863M | $1.00B |
| Revenue growth | — | -15% | -17% | -14% | — |
| Gross profit | $158M | $128M | $136M | $232M | $204M |
| EBITDA | -$59.9M | -$127M | -$175M | -$52.8M | -$137M |
| Net income | -$148M | -$226M | -$53.2M | -$189M | -$328M |
| Free cash flow | -$135M | -$191M | -$208M | -$44.5M | -$120M |
| Capital expenditure | $10.8M | $12.3M | $25.0M | $16.3M | $24.6M |
| Total debt | $516M | $397M | $504M | $327M | $306M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| OPKO Health OPK | $1.25B | +37% | -22% | -29% | 2.8× | n/a |
| Labcorp LH | $30.1B | +44% | +6% | 11% | 2.5× | 14.5% |
| Quest Diagnostics DGX | $28.6B | +34% | +9% | 15% | 2.9× | 7.2% |
| Pfizer PFE | $160B | +9% | +1% | 26% | 3.3× | -4.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | OPK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.8% | -0.2% | 10th highest of 21 |
| 6-month return | +37.4% | +14.4% | 5th highest of 21 |
| Distance from 52-week high | -9.1% | -23.8% | 6th highest of 21 |
| Revenue growth (TTM) | -21.9% | +9.2% | lowest of 21 |
| Operating margin | -29.1% | 5.0% | 2nd lowest of 21 |
| EV / Sales | 2.8× | 1.8× | 6th most expensive of 21 |
| ROIC minus cost of capital | -19.9 pp | -3.4 pp | 3rd lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| OPKO Health OPK | United States | $1.25B | +37% | -22% | -29% | 2.8× | n/a | n/a |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +11% | +20% | 18% | 6.5× | 32.4% | +10.5% |
| Pennant PNTG | United States | $1.26B | +1% | +39% | 6% | 1.5× | 20.7% | +19.4% |
| Diagnostyka DIA.WA | Poland | $1.28B | -6% | +19% | 15% | 2.5× | 7.3% | +18.9% |
| Clariane CLARI.PA | France | $1.32B | -20% | +1% | 6% | 1.6× | 6.8% | +6.5% |
| Nutex Health NUTX | United States | $1.19B | +42% | -19% | 39% | 1.8× | -18.0% | +253.5% |
| Lumexa Imaging LMRI | United States | $1.35B | +89% | +8% | 2% | 2.1× | n/a | n/a |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.36B | -47% | +8% | 3% | 0.4× | 3.5% | -5.1% |
| GoodRx GDRX | United States | $1.15B | +33% | -2% | 12% | 1.8× | 6.3% | +7.7% |
| U.S. Physical Therapy USPH | United States | $1.42B | +53% | +10% | 10% | 2.6× | 18.8% | +13.0% |
| H.U.Group 4544.T | Japan | $1.44B | +24% | +1% | 3% | 1.0× | 9.7% | +2.1% |
| Teladoc Health TDOC | United States | $1.47B | +24% | -2% | -5% | 0.7× | -6.4% | +18.3% |
| agilon health AGL | United States | $1.52B | +12% | +2% | -2% | 0.2× | n/a | n/a |
| GeneDx WGS | United States | $1.56B | +16% | +15% | -14% | 3.5× | n/a | n/a |
| Novogene 688315.SS | China | $1.01B | +13% | +6% | 7% | 2.2× | 13.9% | +8.2% |
| AdaptHealth AHCO | United States | $1.01B | -30% | -3% | 3% | 0.9× | 16.8% | +25.2% |
| Ambea AMBEA.ST | Sweden | $1.59B | +28% | +11% | 9% | 1.7× | 1.1% | +7.7% |
| Sonida Senior Living SNDA | United States | $1.59B | -11% | +70% | -8% | 4.8× | n/a | n/a |
| Personalis PSNL | United States | $1.62B | +88% | +17% | -157% | 18.2× | n/a | n/a |
| Regis Healthcare REG.AX | Australia | $962M | -28% | +17% | 4% | 0.9× | 13.3% | +14.4% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.69B | +18% | +24% | 32% | 17.5× | 40.4% | +16.7% |
OPKO Health has 1 bond outstanding with $121M face value.